We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Pacira (PCRX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Pacira (PCRX - Free Report) to post quarterly earnings of $0.86 per share in its upcoming report, which indicates a year-over-year decline of 3.4%. Revenues are expected to be $184.01 million, up 1.5% from the year-ago quarter.
The current level reflects an upward revision of 5.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Pacira metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Net product sales- EXPAREL' will reach $145.33 million. The estimate points to a change of +1% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Net product sales- ZILRETTA' will reach $30.72 million. The estimate points to a change of +7% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Net product sales- iovera' reaching $6.36 million. The estimate points to a change of +5.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Total net product sales' will likely reach $183.38 million. The estimate indicates a year-over-year change of +2%.
Shares of Pacira have experienced a change of -1.6% in the past month compared to the -1.8% move of the Zacks S&P 500 composite. With a Zacks Rank #1 (Strong Buy), PCRX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Pacira (PCRX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect Pacira (PCRX - Free Report) to post quarterly earnings of $0.86 per share in its upcoming report, which indicates a year-over-year decline of 3.4%. Revenues are expected to be $184.01 million, up 1.5% from the year-ago quarter.
The current level reflects an upward revision of 5.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Pacira metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Net product sales- EXPAREL' will reach $145.33 million. The estimate points to a change of +1% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Net product sales- ZILRETTA' will reach $30.72 million. The estimate points to a change of +7% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Net product sales- iovera' reaching $6.36 million. The estimate points to a change of +5.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Total net product sales' will likely reach $183.38 million. The estimate indicates a year-over-year change of +2%.
View all Key Company Metrics for Pacira here>>>
Shares of Pacira have experienced a change of -1.6% in the past month compared to the -1.8% move of the Zacks S&P 500 composite. With a Zacks Rank #1 (Strong Buy), PCRX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>